Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Abstract

Abstract:A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nanocomposite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure.

Inorganic nanolayers: structure, preparation, and biomedical applications

“…All of these characteristics would improve patients' compliance with treatment, particularly in the management of cancer, TB, and Parkinson's disease, whose drugs have a lot of side effects. 130,[177][178][179] Here, we discuss the effect of different parameters, such as pH, types of anions present in the release media, and mechanisms involved in drug release from LDHs.…”

Nanoparticular Drug Delivery Systems in the Treatment Central Nervous System Diseases: Review

“…8,29,32 Kısa etki süresine sahip konvansiyonel preparatların aksine, reseptörlerin sü-rekli bir şekilde uyarılmasını sağlayan kontrollü salım sistemleri, L-Dopa kaynaklı diskinezilerin azaltılması açısından etkin bir yöntem olarak düşü-nülebilmektedir. 26,30,31 Nano boyuttaki ilaç taşıyıcı sistemler, içerisine yüklenen etken maddeyi dış ortamdan izole ederek enzimatik degredasyondan korunmasını sağ-lamaktadır, bu avantajdan Parkinson hastalığı tedavisinde L-Dopa'nın istenen bölgeye hedeflenmesini sağlayarak periferik dokular üzerindeki yan etkilerinin azaltılması ve beyne istenen dozda ulaş-ması amacıyla yararlanılabilmektedir.…”

Controlled-release formulation of perindopril erbumine loaded PEG-coated magnetite nanoparticles for biomedical applications

“…The cytotoxic effect of the FNPs, FPEGPE nanocomposite, and pure drug (PE) on the cells was measured by the conventional MTT reduction assay as described previously [36]. MTT solution (5 mg mL -1 in phosphate buffered saline-PBS) was added to the treated and control wells at 20 lL final volume and then left in an incubator at 37°C.…”